Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 6, 2013, Pages 777-788

  Bisht, Savita ^a   Feldmann, Georg ^a   Brossart, Peter ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Angiogenesis; Pancreatic neuroendocrine tumors; Platelet derived growth factor receptor; Sunitinib; Targeted therapy; Vascular endothelial growth factor receptor

Indexed keywords

CEDIRANIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; N DEETHYLSUNITINIB; PLACEBO; SUNITINIB; THIAZIDE DIURETIC AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; EPISTAXIS; EUROPE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LUNG EMBOLISM; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PKA; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; TUMOR DIFFERENTIATION; UNITED STATES; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES;

EID: 84877867622     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.791281     Document Type: Review

References (104)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. J Clin Oncol 2008;26(18):3063-72.
2. Bosman FT, Carneiro F, Hruban RH, Theise ND. Who classification of tumors of the digestive system. International Agency for Research on Cancer (IARC), Lyon, France; 2010.
3. Eriksson B, Annibale B, Bajetta E, et al. Enets consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009;90(2):214-19.
4. Kulke MH, Anthony LB, Bushnell DL, et al. Nanets treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39(6):735-52.
5. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130(4):677-82; discussion 682-675.
6. Knigge U, Hansen CP, Stadil F. Interventional treatment of neuroendocrine liver metastases. Surgeon 2008;6(4):232-9.
7. Vilar E, Salazar R, Perez-Garcia J, et al. Chemotherapy and role of the proliferation marker ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007;14(2):221-32.
8. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303(21):1189-94.
9. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79(1):108-18.
10. Chernicoff D, Bukowski RM, Groppe CW Jr, Hewlett JS. Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. Cancer Treat Rep 1979;63(5):795-6.
11. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326(8):519-23.
12. Oberstein PE, Remotti H, Saif MW, Libutti SK. Pancreatic neuroendocrine tumors: entering a new era. JOP 2012;13(2):169-73.
13. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86(6):944-8.
14. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22(23):4762-71.
15. McCollum AD, Kulke MH, Ryan DP, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004;27(5):485-8.
16. Eriksson B, Skogseid B, Lundqvist G, et al. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65(9):1883-90.
17. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13(10):2986-91.
18. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15(1):338-45.
19. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24(3):401-6.
20. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117(2):268-75.
21. Walter T, Bruneton D, Cassier PA, et al. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. Clin Colorectal Cancer 2010;9(4):248-54.
22. de Mestier L, Hammel P, Hentic O, et al. Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency. Gastroenterol Clin Biol 2010;34(1):106-10.
23. Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (dtic) in advanced pancreatic islet cell carcinoma. Study of the eastern cooperative oncology group-e6282. Ann Oncol 2001;12(8):1139-43.
24. Ohshio G, Hosotani R, Imamura M, et al. Gastrinoma with multiple liver metastases: effectiveness of dacarbazine (dtic) therapy. J Hepatobiliary Pancreat Surg 1998;5(3):339-43.
25. Bajetta E, Rimassa L, Carnaghi C, et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998;83(2):372-8.
26. Kurose T, Seino Y, Ishida H, et al. Successful treatment of metastatic glucagonoma with dacarbazine. Lancet 1984;1(8377):621-2.
27. Feldmann G, Bisht S, Schutte U, et al. Everolimus for the treatment of pancreatic neuroendocrine tumors. Expert Opin Pharmacother 2012;13(14):2073-84.
28. Asa SL. Pancreatic endocrine tumors. Mod Pathol 24(Suppl 2):S66-77.
29. Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009;14(5):456-67.
30. Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011;18(2):127-37.
31. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid study group. J Clin Oncol 2009;27(28):4656-63.
32. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23.
33. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13.
34. Joyce JA, Laakkonen P, Bernasconi M, et al. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003;4(5):393-403.
35. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in pdgf-b-deficient mice. Science 1997;277(5323):242-5.
36. Fjallskog ML, Hessman O, Eriksson B, Janson ET. Upregulated expression of pdgf receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 2007;46(6):741-6.
37. Hansel DE, Rahman A, Hermans J, et al. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased vegf-c expression. Mod Pathol 2003;16(7):652-9.
38. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998;32(2):133-8.
39. La Rosa S, Uccella S, Finzi G, et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003;34(1):18-27.
40. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995;9(12):1760-70.
41. Inoue M, Hager JH, Ferrara N, et al. Vegf-a has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1(2):193-202.
42. Couvelard A, O'Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and vegf expression with tumour progression. Br J Cancer 2005;92(1):94-101.
43. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315(6015):115-22.
44. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-95.
45. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31.
46. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23(5):939-52.
47. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of vegf inhibition. J Clin Invest 2006;116(10):2610-21.
48. Franco M, Roswall P, Cortez E, et al. Pericytes promote endothelial cell survival through induction of autocrine vegf-a signaling and bcl-w expression. Blood 2011;118(10):2906-17.
49. Franco M, Paez-Ribes M, Cortez E, et al. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 2011;43(12):884-9.
50. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007;109(8):1478-86.
51. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of vegf signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309.
52. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26(8):1316-23.
53. Deeks ED, Raymond E. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. BioDrugs 2011;25(5):307-16.
54. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6(9):734-45.
55. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3z)-ylidenemethyl]-2,4- dimethyl-1h-pyrrole-3-carboxylic acid (2- diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46(7):1116-19.
56. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of su11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37.
57. Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor su11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7(3):225-33.
58. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of su11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005;11(16):5827-32.
59. Abrams TJ, Lee LB, Murray LJ, et al. Su11248 inhibits kit and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2(5):471-8.
60. Murray LJ, Abrams TJ, Long KR, et al. Su11248 inhibits tumor growth and csf-1r-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20(8):757-66.
61. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, su11248, is a novel potent inhibitor of thyroid oncogenic ret/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91(10):4070-6.
62. O'Farrell AM, Abrams TJ, Yuen HA, et al. Su11248 is a novel flt3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101(9):3597-605.
63. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor su11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2(10):1011-21.
64. Rini BI. Sunitinib. Expert Opin Pharmacother 2007;8(14):2359-69.
65. Tuveson D, Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 2011;471(7338):316-17.
66. Haznedar JO, Patyna S, Bello CL, et al. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 2009;64(4):691-706.
67. Speed B, Bu HZ, Pool WF, et al. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos 2012;40(3):539-55.
68. Patyna S, Peng G. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys (abstract 56). Eur J Cancer Suppl 2006;4(12):21.
69. Shapiro BH, Agrawal AK, Pampori NA. Gender differences in drug metabolism regulated by growth hormone. Int J Biochem Cell Biol 1995;27(1):9-20.
70. Bullock P, Pearce R, Draper A, et al. Induction of liver microsomal cytochrome p450 in cynomolgus monkeys. Drug Metab Dispos 1995;23(7):736-48.
71. Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in cyp450 isoforms in humans. Expert Opin Drug Metab Toxicol 2008;4(4):413-24.
72. Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008;61(3):515-24.
73. Baratte S, Sarati S, Frigerio E, et al. Quantitation of su1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A 2004;1024(1-2):87-94.
74. Morimoto AM, Tan N, West K, et al. Gene expression profiling of human colon xenograft tumors following treatment with su11248, a multitargeted tyrosine kinase inhibitor. Oncogene 2004;23(8):1618-26.
75. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (su11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17(3):353-8.
76. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of su11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35.
77. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24.
78. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329- 38.
79. Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010;50(4):472-81.
80. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13(5):1367-73.
81. Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (su11248) and its primary metabolite (su12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009;15(7):2497-506.
82. Bello CL, Garrett M, Sherman L, et al. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol 2010;66(4):699-707.
83. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26(20):3403-10.
84. Washington C, Eli M, Bello C, et al. The effect of ketoconazole (keto), a potent cyp3a4 inhibitor, on su011248 pharmacokinetics (pk) in caucasian and asian healthy subjects. Proc Am Soc Clin Soc 2003;22:Abstract 138.
85. Bello CHB, Sherman L, et al. Effect ofrifampin on the pharmacokinetics of su11248 in healthy volunteers. Presented at: ASCO Annual Meeting; 13 - 17 May 2005; Orlando, Fla; Abstract 3078.
86. Gangadhar TC, Cohen EE, Wu K, et al. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res 2011; 17(7):1956-63.
87. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (sutent, su11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the atp-binding cassette (abc) transporters p-glycoprotein (abcb1) and abcg2. Drug Metab Dispos 2009;37(2):359-65.
88. Aparicio-Gallego G, Blanco M, Figueroa A, et al. New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther 2011;10(12):2215-23.
89. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7(3):193-201.
90. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011;10(3):151-6.
91. Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol 2009;27(36):6152-9.
92. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 2006;40(12):2278-9.
93. Curwen JO, Musgrove HL, Kendrew J, et al. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; azd2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 2008;14(10):3124-31.
94. Aaronson NK, Ahmedzai S, Bergman B, et al. The european organization for research and treatment of cancer qlq-c30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-76.
95. Vinik A, Van Cutsem E, Niccoli P, et al. Progression-free survival (pfs) by blinded independent central review (bicr) and updated overall survival (os) of sunitinib versus placebo for patients with progressive, unresectable, well differentiated pancreatic neuroendocrine tumor (net). Pancreas 2012;41(2):350-0.
96. Faivre S, Niccoli P, Raoul JL, et al. Updated overall survival (os) analysis from a phase III study of sunitinib vs placebo in patients (pts) with advanced, unresectable pancreatic neuroendocrine tumor (net). Ann Oncol 2012;23:376.
97. Dreyer C, Hentic O, Zappa M, et al. Response evaluation using recist and choi criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pnet) treated with sunitinib or everolimus. Ann Oncol 2012;23:379.
98. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67(5):2187-96.
99. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor gdc-0449. N Engl J Med 2009;361(12):1173-8.
100. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324(5933):1457-61.
101. Cook N, Frese KK, Bapiro TE, et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Mede 2012;209(3):437-44.
102. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9(6):338-50.
103. Kamiyama H, Rauenzahn S, Shim JS, et al. Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res 2013;19(5):1139-46.
104. Jiao Y, Shi C, Edil BH, et al. Daxx/atrx, men1, and mtor pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331(6021):1199-203.